Designing neutralization antibodies against Sars-Cov-2

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI158114-01

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2023
  • Known Financial Commitments (USD)

    $433,750
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Wei Wang
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF CALIFORNIA, SAN DIEGO
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary COVID-19 has become a worldwide pandemic whose rapid spread and mortality rate threatens millions of lives and the global economic system. Developing effective treatment such as neutralization antibodies is an urgent need. We propose here to develop a new method to design antibodies strongly bind to the SARS-CoV-2 receptor binding domain (RBD) that is necessary for viral entrance to human cells. We will develop a novel approach that combines directed evolution, deep sequencing and interpretable neural network models to efficiently identify strong and specific antibodies. This method will allow analyzing large sequencing data sets of antibody variants against the SARS-CoV-2 RBD in order to derive superior binders that do not exist in the original library. Iteration through directed evolution and computational design will efficiently identify neutralization antibody candidates that can be used as potent therapeutics to treat COVID-19.